Kronos Bio Inc expected to post a loss of 51 cents a share - Earnings Preview

Kronos Bio

03/11/2023 12:44

* Kronos Bio Inc  KRON.OQ   KRON.O  is expected to show a
rise in
quarterly revenue when it reports  results 
    * The San Mateo California-based  company is expected to
report
revenue of $1.4 million, according to the mean estimate from 4
analysts, based on LSEG data.  
    * ​Refinitiv's mean analyst estimate for Kronos Bio Inc is
for a
loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kronos Bio
Inc is
$8.5​, above​ its last closing price of $0.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.43       -0.46      -0.52     Missed  -13
 Mar. 31 2023  -0.27       -0.44      -0.46     Missed  -3.4
 Dec. 31 2022  -0.48       -0.59      -0.56     Beat    4.4​
 Sep. 30 2022  -0.65       -0.65      -0.57     Beat    12.6
 ​​Jun.        -0.69       -0.69      -0.59     Beat    14.7
 30 2022                                                
 Mar. 31 2022  -0.65       -0.66      -0.65     Beat    1.2​
 Dec. 31 2021  -1.08       -1.10      -1.13     Missed  -2.9
 Sep. 30 2021  -0.99       -1.01      -0.61     Beat    39.7
 This summary was machine generated November 3 at 12:44 GMT.  All
figures in US dollars  unless otherwise stated